Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Novartis Ag
Novartis Ag_20100107
Novartis Ag And The Jackson Laboratory
Novartis Ag_20100114
Novartis Ag_20100121
Novartis Ag_20131212
Novartis Ag_20100128

Novartis Ag patents


Recent patent applications related to Novartis Ag. Novartis Ag is listed as an Agent/Assignee. Note: Novartis Ag may have other listings under different names/spellings. We're not affiliated with Novartis Ag, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Novartis Ag-related inventors


 new patent  Novartis Ag

. . ... Novartis Ag

 new patent  Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (i) and (b) a mtor inhibitor for the treatment of a target of rapamycin (mtor) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.. . ... Novartis Ag

 new patent  Drug delivery systems

The present invention relates to thermogelling peptide delivery systems which are injected as fluid sol at ambient temperature through thin injection needles and transform into a highly viscous gel once inserted into human or animal body warm tissue. In a preferred embodiment said system is based on the use of a hydrophobic peptide, a chitosan and a glucose-phosphate.. ... Novartis Ag

 new patent  Medical instrument with an integrated optical fiber

In some embodiments, an illuminated microsurgical instrument system includes a microsurgical instrument having a distally projecting tubular member arranged to perform a medical procedure. The tubular member has a distal tip and an outer surface, the outer surface having a flat surface formed therein. ... Novartis Ag

 new patent  Medical instrument with an integrated optical fiber

Provided herein is an illuminated microsurgical instrument system and an illuminated microsurgical instrument. In one implementation, the system includes a microsurgical instrument having a distally projecting tubular member arranged to perform a medical procedure at an interventional site. ... Novartis Ag

 new patent  Tri-axial ergonomic footswitch

A foot-operated controller includes a base configured to rest on a floor surface, and a movable contact surface coupled to the base. The contact surface includes an anterior region to support a toe region and a posterior region to support a heel region, and is configured to roll about a roll axis in response to inversion or eversion of a foot engaged with the contact surface, pitch about a pitch axis in response to plantar flexion or dorsiflexion of the foot, and yaw about a yaw axis in response to abduction or adduction of the foot. ... Novartis Ag

 new patent  Ergonomic foot-operated joystick

A method and system provide a surgical system including a foot pedal and at least one pressure sensor. The foot pedal has a first axis and a second axis. ... Novartis Ag

Novartis Ag

. . ... Novartis Ag

Novartis Ag

. . ... Novartis Ag

Convergence-sensing electro-active accommodating lens

A lens system comprises a first electro-active lens comprising a first focus sensor coupled to a first processor and a second electro-active lens comprising a second focus sensor coupled to a second processor. The first focus sensor periodically generates electromagnetic signals and detects electectromagnetic signals generated by the second focus sensor. ... Novartis Ag

Fibronectin-based binding molecules and uses thereof

The invention provides fibronectin type iii (fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific fn3-based binding molecules that bind to two or more targets simultaneously. ... Novartis Ag

Antibody drug conjugates

The present invention relates to anti-ckit antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. . ... Novartis Ag

Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy

The present invention relates to an oxazine derivative bace-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the apoe4 allele.. . ... Novartis Ag

Sacubitril-valsartan dosage regimen for treating heart failure

The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.. . ... Novartis Ag

05/03/18 / #20180120590

Method for producing contact lenses with wearing comfort

The invention is related to a method for producing silicone hydrogel contact lenses with a stable lubricious hydrogel coating thereon providing a low surface friction. A method of the invention comprises forming a plasma-reactive hydrophilic polymer hybrid base coating having reactive functional groups on a silicone hydrogel contact lens and heating the silicone hydrogel contact lens with the hybrid base coating in an aqueous solution of a water-soluble and thermally crosslinkable hydrophilic polymeric material to form a stable lubricious hydrogel coating thereon.. ... Novartis Ag

05/03/18 / #20180120199

Contact lens inspection method and system

A method for determining the inversion state of a soft contact lens (1), comprising imaging a soft contact lens having a convex surface (2, 3) and a concave surface (3, 2), a lens center and a lens edge (5) surrounding said soft contact lens (1), the method comprising using an optical coherence tomography system to obtain at least one sectional image of at least a part of the contact lens (1) comprising the lens edge (5), determining a cross-sectional edge geometry of the contact lens (1) extending from the lens edge (5) towards the lens center of the contact lens in the sectional image, the cross-sectional edge geometry corresponding to the convex and concave surface boundaries of the contact lens (1) in the sectional image, selecting a parameter defining the cross-sectional edge geometry of the contact lens (1) imaged and comparing the parameter defining the cross-sectional edge geometry of the contact lens (1) with a predetermined parameter defining a cross-sectional edge geometry of a non-inverted contact lens to determine whether said contact lens (1) is inverted.. . ... Novartis Ag

05/03/18 / #20180118843

Silent fc variants of anti-cd40 antibodies

The present invention relates to silent fc variants of anti-cd40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.. . ... Novartis Ag

05/03/18 / #20180118678

Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid

This invention relates to a hemifumarate salt of 1-(4- 1-[(e)-cyclohexyl-3-tritluoromethy 1-benzy loxyimino ]-ethy 1)-2-ethy1-benzy l)-azetidine-3-carboxy lie acid (compound) to pharmaceutics compositions comprising this salt, to processes for forming this salt and to its use in medical treatment, addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of compound i, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.. . ... Novartis Ag

05/03/18 / #20180117059

Methods for treating egfr mutant cancers

Methods for the treatment of egfr mutated cancer. For example, treatment of non-small cell lung cancer (nsclc) with activating egfr mutations (e.g., l858r and ex19del) the acquired or resistant “gatekeeper” t790m mutation, or any combination of these mutations.. ... Novartis Ag

05/03/18 / #20180117011

Enzalutamide in combination with afuresertib for the treatment of cancer

A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt thereof, and an akt inhibiting compound, for example: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or akt inhibition is beneficial, e.g., cancer.. . ... Novartis Ag

05/03/18 / #20180117009

3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Disclosed are novel pharmaceutical compositions containing 3′-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinol]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.. . ... Novartis Ag

04/19/18 / #20180106790

Single chain proteins with c-terminal modifications

The invention pertains to an isolated vh single domain antibody comprising a c-terminal modification, where the c-terminal modification comprises a deletion of at least one amino acid residue that eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.. . ... Novartis Ag

04/19/18 / #20180105620

Hydrophilic copolymer with pendant thiol groups

The invention is related to a class of hydrophilic copolymers comprising loosely dangling thiol-containing pendant groups. The hydrophilic copolymers are highly reactive towards azetidinium groups of an azetidinium-containing polymer upon heating and can find particular use in for producing water-soluble highly-branched hydrophilic polymeric material useful for producing water gradient contact lenses.. ... Novartis Ag

04/19/18 / #20180105619

Hydrophilic copolymer with one thiol-containing terminal group

The invention is related to a class of hydrophilic polymers each comprising one sole thiol-containing terminal group. The hydrophilic polymers are highly reactive towards azetidinium groups of an azetidinium-containing polymer upon heating and can find particular use in for producing water-soluble highly-branched hydrophilic polymeric material useful for producing water gradient contact lenses.. ... Novartis Ag

04/19/18 / #20180104920

Method for producing contact lenses

The invention provides a method producing contact lenses, including the step of: holding the molded silicone hydrogel contact lens attached to the one of the female mold half or the male mold half with a vacuum supplied with a suction cup; deforming a surface of the one of the female mold half or the male mold half having the molded silicone hydrogel contact lens attached to with a pin so as to separate the molded silicone hydrogel contact lens from the mold half attached to and to transfer the molded silicone hydrogel contact lens to the suction cup; moving the suction cup away from the pin while the suction cup continues to hold the molded silicone hydrogel contact lens remains; applying a compressed gas to blow the molded silicone hydrogel contact lens away from the suction cup into a container.. . ... Novartis Ag

04/19/18 / #20180104919

Method for producing contact lenses

The invention provides a process for casting—molding contact lenses with enhanced quality and enhanced yield achieved by omitting the previously required check to discover on or in which mold half the contact lens is located after the mold has been opened. The process of the invention includes: providing a mold including a first mold half having a first molding surface and a second mold half having a second molding surface, wherein the first and second mold halves are configured to receive each other such that a mold cavity is formed between the first and second molding surfaces, wherein one of the first and second mold halves has a collar that encircles the other mold half to provide a seal between the two mold halves when the mold is closed; dispensing a polymerizable lens-forming material into one of the mold halves; mating the mold halves to close the mold; polymerizing the polymerizable material located between the two mold halves, thereby forming a molded contact lens; applying a force to non-optical surface of the female mold with a pin at a location about the center area of non-optical molding surface of the mold to deform the female mold thereby breaking the bonds between the optical molding surface of the female mold and the lens and opening the mold.. ... Novartis Ag

04/19/18 / #20180104388

Apparatus for controlling vacuum during ocular surgery

A method and system assist a physician in controlling pressure in a line during a surgery. The method includes filtering a vacuum signal such that portions of the vacuum signal having a frequency greater than a threshold frequency (e.g., ten hz) are not passed. ... Novartis Ag

04/19/18 / #20180104103

Internal shunt and method for treating glaucoma

A surgical technique and device wherein an indwelling tube is placed in the eye of a patient having glaucoma. The tube diverts aqueous humor from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. ... Novartis Ag

04/19/18 / #20180104101

Formed cutter for vitrectomy probe

Vitreoretinal probes and methods related thereto are disclosed herein. A vitreoretinal probe may include a needle and a cutter slidably disposed within the needle. ... Novartis Ag

04/19/18 / #20180104100

Optical coherence tomography cross view imaging

An optical coherence tomography (oct) system and method for cross view imaging using at least two b-scan images transformed and coupled to each other at an angle to generate a cross view image.. . ... Novartis Ag

04/19/18 / #20180103972

Surgical instrument having a surface texture

Surgical instruments and, particularly, ophthalmic surgical instruments are disclosed. Example surgical instruments include forceps for removal of an internal limiting membrane (ilm). ... Novartis Ag

04/19/18 / #20180103844

Mechanical support of an indirect contact lens by a surgical microscope during vitreoretinal surgery

An indirect contact lens is mechanically coupled to a surgical microscope during ophthalmic surgery, such as vitreoretinal surgery. The indirect contact lens rests on a cornea of an eye of a patient during the surgery but is supported by a surgical microscope attachment having multiple degrees of freedom to accommodate small movements of the eye while remaining aligned to an optical axis of the surgical microscope.. ... Novartis Ag

04/19/18 / #20180103842

Scanning optical probe with flexing mechanism

A scanning optical probe and method includes a cannula, optical fiber, lens, and an actuating mechanism for tilting the optical fiber back and forth within the cannula. An actuator in the probe handle is coupled to various flexing and guide components extending through the cannula and towards the distal end of the scanning optical probe. ... Novartis Ag

04/12/18 / #20180100053

Chain-extended polydimethylsiloxane vinylic crosslinkers and uses thereof

The invention provides a chain-extended polydiorganosiloxane vinylic crosslinker which comprises (1) a polymer chain comprising at least two polydiorganosiloxane segments and one hydrophilized linker between each pair of polydiorganosiloxane segements, wherein each polydiorganosiloxane comprises at least 5 dimethylsiloxane units in a consecutive sequence, wherein the hydrophilized linker is a divalent radical having at least two (meth)acrylamide moieties; (2) two terminal (meth)acryloyl groups, wherein the chain-extended polydiorganosiloxane vinylic crosslinker has an average molecular weight of at least about 1500 daltons. The present invention is also related to a silicone hydrogel contact lens, which comprises repeating units derived from a chain-extended polydiorganosiloxane vinylic crosslinker of the invention. ... Novartis Ag

04/12/18 / #20180100038

Polymerizable polydimethylsiloxane-polyoxyalkylene block copolymers

The invention provides a polymerizable polydimethylsiloxane-polyoxyalkylene block copolymer which comprises (1) a linear polymer chain comprising at least two polydimethylsiloxane segments, one hydrophilic polyoxyalkylene segment between each pair of polydimethylsiloxane segments, and one amide-rich linker between each pair of one polydimethylsiloxane segment and one hydrophilic polyoxyalkylene segment, and (2) two terminal (meth)acryloyl groups. The hydrophilized polydiorganosiloxane vinylic crosslinker has a weight average molecular weight of at least 3000 daltons. ... Novartis Ag

04/12/18 / #20180098995

Combination products with tyrosine kinase inhibitors and their use

The present invention relates to pharmaceutical products comprising a combination of (i) a met inhibitor and (ii) an egfr inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related invention embodiments.. . ... Novartis Ag

04/05/18 / #20180092775

Glaucoma treatment device

Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. ... Novartis Ag

04/05/18 / #20180092702

Systems and methods for a surgical tissue manipulator

An apparatus for manipulating tissue during a procedure performed within an eye of a patient is disclosed herein. The apparatus includes a hand-held controller and an elongate member configured to be inserted into the eye of the patient. ... Novartis Ag

04/05/18 / #20180092524

Ocular modeling methods and apparatus

A method and apparatus for modelling a lens (104) of an eye (100), comprising: measuring (302) the anterior shape of the eye's cornea (102); determining (304) direct optical measurements of at least one parameter of the cornea (102) of the eye (100) and at least one parameter of the lens (104) of the eye (100); determining (306) the refractive index of the cornea; correcting (308) the optical measurements to account for the effect of the refractive index of the cornea on the direct optical measurements; measuring (310) the aberration of the eye; calculating (312) the refractive index of the lens by combining the corrected measurements and the aberration; and further correcting (314) the optical measurements of the lens to account the effect of the refractive index of the lens on the direct optical measurements.. . ... Novartis Ag

03/29/18 / #this invention pertains generally to compounds of formula (a),

Novartis Ag

. . ... Novartis Ag

03/29/18 / #the present invention provides a compound of formula (i) in free form or in pharmaceutically acceptable salt form

Novartis Ag

. . ... Novartis Ag

03/29/18 / #the invention relates to a combination which comprises:

Novartis Ag

. . ... Novartis Ag

03/29/18 / #20180085362

Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (pi3k) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mtor) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mtor) kinase dependent diseases.. . ... Novartis Ag

03/29/18 / #20180085213

Heat tunable intraocular lens

A method and system provide an ophthalmic lens including a lens body having a chamber therein, a reservoir module coupled with the lens body and an optical fluid. At least part of the lens body is flexible. ... Novartis Ag

03/22/18 / #the present invention relates to 1-aza-bicycloalkyl derivatives of formula i,

Novartis Ag

. . ... Novartis Ag

03/22/18 / #20180083621

Wireless ophthalmic surgical footswitch

Disclosed is a surgical footswitch, comprising a base, a pedal mounted to the base, and a variable air capacitor mechanically coupled to the pedal, such that movement of the pedal is operative to vary the capacitance of the variable air capacitor. The footswitch further comprises a capacitance-sensing controller circuit electrically connected to the variable air capacitor and configured to measure a capacitance of the variable air capacitor and to produce a control signal based on the measured capacitance, such that the control signal reflects a position of the pedal or a change in the position of the pedal, and a wireless interface electrically connected to the capacitance-sensing controller circuit and configured to wirelessly relay the control signal to a surgical console.. ... Novartis Ag

03/22/18 / #20180081197

Process for producing contact lenses with durable lubricious coatings thereon

The invention is related to a method for producing soft contact lenses comprises a silicone hydrogel lens body and a composite coating thereon. The composite coating comprises: a plasma base coating which is chemically-attached directly onto the surface of the silicone hydrogel contact lens and functions as a fail-proof measure for ensuring the hydrophobic silicone hydrogel lens material to be shielded from any exposure to ocular environments even after at least 30 days of daily uses including daily waring and daily cleaning/disinfecting; and a relatively-durable lubricious hydrogel top coating for ensuring wearing comfort. ... Novartis Ag

03/22/18 / #20180080046

Viral vectors for the treatment of retinal dystrophy

The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering rlbp1 to rpe and müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. ... Novartis Ag

03/22/18 / #20180080013

Rna-guided gene editing system and uses thereof

The present invention provides rna-guided gene editing systems and methods of use thereof.. . ... Novartis Ag

03/22/18 / #20180079889

Method for producing a water-soluble thermally-crosslinkable polymeric material

The invention is related to a cost-effective method for producing water-soluble thermally-crosslinkable hydrophilic polymeric materials. Resultant materials can find particular use in preparing a packaging solution used for packaging and autoclaving medical devices, especially contact lenses. ... Novartis Ag

03/22/18 / #20180079799

Polyomavirus neutralizing antibodies

The present invention relates to anti-vp1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.. . ... Novartis Ag

03/22/18 / #20180079158

Hydrogel contact lenses with lubricious coating thereon

The invention is generally related to soft contact lenses which comprise a non-silicone hydrogel lens body and a hydrogel coating thereon. The non-silicone hydrogel lens body is composed of a hydrogel material which is free of silicone and comprises at least 50% by mole of repeating units of at least one hydroxyl-containing vinylic monomer. ... Novartis Ag

03/22/18 / #20180079157

Colored hydrogel contact lenses with lubricious coating thereon

The invention is generally related to colored contact lenses which comprise a hydrogel lens body having an opaque color image therein and/or thereon and a durable lubricious coating thereon. The coating comprises an anchoring layer of a polyanionic polymer having carboxyl groups and a hydrogel layer which is derived from a hydrophilic polymeric material having azetidinium groups and is covalently attached onto the anchoring layer of the polyanionic polymer through linkages each formed between one carboxyl group and one azetidinium groups. ... Novartis Ag

03/22/18 / #20180078540

Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (i) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (i) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (i) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.. . ... Novartis Ag

03/22/18 / #20180078315

Systems and methods for tracking the orientation of surgical tools

Methods, devices, and systems for determining an orientation of a surgical tool during ophthalmic surgery are disclosed. An example method includes performing an optical imaging scan in the surgical site, using a scan pattern that intersects the surgical tool and generating a scan image from the optical imaging scan. ... Novartis Ag

03/22/18 / #20180078130

Subtractive en face optical coherence tomography imaging

En face or 3d volumetric oct imaging during ophthalmic surgery may be performed with an oct scanning controller that interfaces to an oct scanner used with a surgical microscope. The oct scanner may generate en face images before and after surgical operations, such as retinal membrane peeling, are performed. ... Novartis Ag

03/15/18 / #the invention relates to heterocyclic compounds of the formula (i)

Novartis Ag

. . ... Novartis Ag

03/15/18 / #a medicament comprising, separately or together (a) glycopyrrolate; and

Novartis Ag

. . ... Novartis Ag

03/15/18 / #20180071296

Combination therapy comprising an inhibitor of jak, cdk, and pim

The present invention relates to a pharmaceutical combination which comprises (a) a jak inhibitor compound, (b) a cdk inhibitor, and (c) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.. . ... Novartis Ag

03/15/18 / #20180071251

Combination of lbh589 with other therapeutic agents for treating cancer

The invention relates to a combination comprising the n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2e-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.. . ... Novartis Ag

03/15/18 / #20180071143

Ocular implant with stiffness qualities, methods of implantation and system

Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. ... Novartis Ag

03/08/18 / #the present invention relates to compounds of formula i:

Novartis Ag

. . ... Novartis Ag

03/08/18 / #the invention provides the use of compound of formula v or formula vi in the treatment of a demyelinating peripheral neuropathy:

Novartis Ag

. . ... Novartis Ag

03/08/18 / #20180066067

Antibodies and methods for wnt pathway-related diseases

The transmembrane e3 ubiquitin ligases znrf3 and rnf43 are negative regulators of β-catenin and the wnt signaling pathway in eukaryotic cells. The activity of znrf3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in wnt signaling. ... Novartis Ag

03/08/18 / #20180066061

Methods of treating sporadic inclusion body myositis

The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an actrii receptor binding molecule, an actrii receptor antibody, such as the bimagrumab antibody.. . ... Novartis Ag

03/01/18 / #the invention provides compounds of formula (i):

Novartis Ag

. . ... Novartis Ag

03/01/18 / #20180062344

Ophthalmic illumination system with controlled chromaticity

An ophthalmic illumination system includes a broadband light source configured to emit a white laser beam, a first monochromatic light source configured to emit a first monochromatic laser beam having a first central wavelength, optics configured to receive a combined light beam comprising the white laser beam and the monochromatic laser, and a controller comprising a processor and a memory configured to control a chromaticity of the combined light beam by changing an output power of the first monochromatic light source.. . ... Novartis Ag

03/01/18 / #20180059436

Contact lens packaging solutions

The present invention relates to improved contact lens products which not only have an improved and sustainable wettability. The contact lens product of the invention comprises a soft hydrogel contact lens immersed and autoclaved in a packaging solution including a polyoxyethylene-polyoxybutylene block copolymer and a high molecular weight copolymer of n-vinylpyrrolidone and at least one amino-containing vinylic monomer. ... Novartis Ag

03/01/18 / #20180058627

Locking nut and washer

An articulated mechanism and associated systems and methods therefore are disclosed. An example articulating mechanism within the scope of the disclosure includes a stud, a keyed washer having a plurality of threaded apertures, and a nut. ... Novartis Ag

03/01/18 / #20180058438

Handheld ophthalmic probe with peristaltic pump and associated devices, systems, and methods

Systems, apparatuses, and methods of and for an ophthalmic surgical system are disclosed. An ophthalmic surgical system may include a handheld probe. ... Novartis Ag

03/01/18 / #20180057477

Heterocyclic compounds and methods for their use

The present invention relates to heterocyclic compounds useful for antagonising angiotensin ii type 2 (at2) receptor. More particularly the invention relates to compounds of formula (i), as described herein, compositions containing them and their cm use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.. ... Novartis Ag

03/01/18 / #20180057457

Chemical process for preparing pyrimidine derivatives and intermediates thereof

The present disclosure relates to a method of synthesizing 5-chloro-n2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.. . ... Novartis Ag

03/01/18 / #20180056613

Process for dispensing a contact lens forming fluid material

A method for dispensing a material into a mold for forming contact lenses, comprises the steps of: (1) providing a contact lens mold, (2) providing a dispensing needle, wherein the dispensing needle is made from a material having a surface energy less than 32 dynes/cm, (3) arranging the contact lens mold underneath the dispensing needle, (4) dispersing a fluid composition into a mold for making a contact lens, wherein the fluid composition comprises a lens-forming material, and the lens-forming material containing a solvent and is crosslinkable and/or polymerizable by thermal curing or actinic radiation.. . ... Novartis Ag

03/01/18 / #20180055769

Circulation of components during microfluidization and/or homogenization of emulsions

An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.. ... Novartis Ag

03/01/18 / #20180055688

Systems and methods for non-invasive measurement of cassette pressure

A method and system provide a surgical system including a cassette, a console and an interferometric pressure sensing system coupled with the console. The cassette is for exchanging material with a patient and includes a wall and a reflector. ... Novartis Ag

03/01/18 / #20180055596

Planar illuminator for ophthalmic surgery

The present disclosure provides illumination apparatus for ophthalmic surgery comprising a light that provides planar field illumination, as well as methods of using the illumination apparatus. The illuminators of the present disclosure can be used in intraocular refractive and vitroretinal surgery to better enable visualization of anatomical structures of the eye currently difficult to view, capturing detail that would normally be obscured using conventional illumination apparatus.. ... Novartis Ag

03/01/18 / #20180055592

Surgical probe with an integrated motion sensor

A surgical probe system comprising a surgical probe having an instrument tip, and at least one motion sensor located within the surgical probe that measures movement and orientation data. The system further includes a processor that is configured to determine movement and orientation of the instrument tip based on the movement and orientation data, and adjust at least one surgical parameter of the surgical probe based on the movement and orientation of the instrument tip to affect a predetermined surgical outcome.. ... Novartis Ag

03/01/18 / #20180055581

Predictive apparatus for assisting a physician during ophthalmic surgery

A method and system assist a physician in performing an ophthalmic surgery. The method includes receiving a quasi-real time image of at least a first portion of the eye. ... Novartis Ag

02/22/18 / #the invention is directed to a formula (i):

Novartis Ag

. . ... Novartis Ag

02/22/18 / #20180051092

Methods of treatment by administering an anti-baffr antibody therapeutic formulation

Anti-baffr antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.. ... Novartis Ag

02/22/18 / #20180049921

Phacoemulsification hand piece with integrated aspiration pump

An ophthalmic surgical hand piece comprises a driver coupled to a horn. The horn is coupled to a needle. ... Novartis Ag

02/22/18 / #20180049920

Surgical apparatus including aspiration device sensors

A method and system provide a surgical hand piece including an aspiration line, a tip and a sensor. The tip is coupled with the aspiration line. ... Novartis Ag

02/22/18 / #20180049919

Articulating ophthalmic surgical probe

An articulating optical surgical probe includes a handle sized to fit in a single hand and a single rigid cannula extending from the handle having a diameter of 20 ga or less. The probe further includes a slotted tip at a distal end of the cannula and at least one optical fiber extending through the handle, the single rigid cannula and the slotted tip, and a pull-wire secured to the slotted tip. ... Novartis Ag

02/22/18 / #20180049866

Systems and methods for deployment damping in intraocular lens deployment

Intraocular lens (iol) insertion apparatus and methods of use are provided and described herein. An example iol insertion apparatus may include a handpiece body having a distal tip, a deployment chamber having an opening at a distal end of the handpiece body, and a deployment system disposed within the handpiece body. ... Novartis Ag

02/22/18 / #20180049865

Synthetic flap for trabeculectomy procedures

A method includes forming a conjunctival incision in a patient's eye, attaching a synthetic flap to the patient's eye within the conjunctival incision, forming a scleral tunnel underneath the synthetic flap, the scleral tunnel extending from an exterior of a sclera to an anterior chamber of the patient's eye, and closing the conjunctival incision.. . ... Novartis Ag

02/22/18 / #20180049864

Devices, systems, and methods for trabecular meshwork extension

Described herein is an extension device to extend ocular tissue within an irideocorneal angle of an eye of a patient, comprising a flexible body and a plurality of tensioning features disposed on the body. The body is sized and configured to be disposed within the irideocorneal angle. ... Novartis Ag

02/15/18 / #20180045927

Surgical microscope with integrated optical coherence tomography and display systems

An ophthalmic surgical microscope includes a beam coupler positioned along an optical path of the surgical microscope between a first eyepiece and magnifying/focusing optics, the beam coupler operable to direct the oct imaging beam along a first portion of the optical path of the surgical microscope between the beam coupler and a patient's eye (an oct image being generated based on a reflected portion of the oct imaging beam). The surgical microscope additionally includes a real-time data projection unit operable to project the oct image generated by the oct system and a beam splitter positioned along the optical path of the surgical microscope between a second eyepiece and the magnifying/focusing optics. ... Novartis Ag

02/15/18 / #20180044549

Silicone hydrogel lenses with water-rich surfaces

The invention is related to a hydrated silicone hydrogel contact lens having a layered structural configuration: a lower water content silicone hydrogel core (or bulk material) completely covered with a layer of a higher water content hydrogel totally or substantially free of silicone. A hydrated silicone hydrogel contact lens of the invention possesses high oxygen permeability for maintaining the corneal health and a soft, water-rich, lubricious surface for wearing comfort.. ... Novartis Ag

02/15/18 / #20180044410

Angiopoietin-like 4 antibodies and methods of use

The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “angptl4”), and pharmaceutical compositions and methods of treatment comprising the same.. . ... Novartis Ag

02/15/18 / #20180042895

Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.. . ... Novartis Ag

02/15/18 / #20180042768

Subretinal fluid drainage instruments, systems, and methods

A surgical instrument for removal of subretinal fluid is provided herein. The surgical instrument may include a handle coupleable to an aspiration source and a first elongate tubular member having a proximal end and a distal end, the proximal end being coupled to the rotational structure such that the first elongate tubular member is rotatable around the axis. ... Novartis Ag

02/08/18 / #20180039060

Extraction of microscope zoom level using object tracking

A method and system for extracting the zoom level of a microscope is disclosed. The method includes capturing a reference image; recording a first zoom level corresponding to a first magnification at which the reference image is captured; capturing a second image; determining a second zoom level by comparing the second image and the reference image, the second zoom level corresponding to a second magnification at which the second image is captured; and recording the second zoom level at a location accessible by a microscope application.. ... Novartis Ag

02/08/18 / #20180037957

Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment

The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.. . ... Novartis Ag

02/08/18 / #20180037623

Methods and compositions using klotho variant polypeptides

The present disclosure is directed to compositions and methods related to an alpha sklotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the c-terminus, optionally also having mutations at v563 and/or k795. The present disclosure also pertains to an alpha sklotho polypeptide variant or fragment, having mutations at v563 and/or k795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the c-terminus. ... Novartis Ag

02/08/18 / #20180036315

Oxazine derivative for use in the prevention of alzheimer's disease in at risk patients

The present invention relates to an oxazine derivative bace-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of alzheimer's disease in a patient at risk of developing clinical symptoms of alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of alzheimer's disease carries one or two copies of the apoe4 allele.. . ... Novartis Ag

02/08/18 / #20180036230

Octreotide depot formulation with constantly high exposure levels

The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (plgas).. . ... Novartis Ag

02/08/18 / #20180036170

Enhancing performance of a capsulotomy device

The present disclosure provides a capsulotomy device having a unique insertion sleeve configuration comprising beveling and two notches at the distal end of the insertion sleeve. The unique configuration assures that the motion the capsulotomy loop comprising the heating element goes through during deployment from and retraction into the insertion sleeve is minimized and predictable.. ... Novartis Ag

02/01/18 / #the present invention provides a compound of formula (i) or a salt thereof;

Novartis Ag

. . ... Novartis Ag

02/01/18 / #the invention provides compounds of formula (i)

Novartis Ag

. . ... Novartis Ag

02/01/18 / #20180031863

Toric contact lens having a ballast mark representing a lens identification code

A toric contact lens (1) having a front surface and a rear surface, one of said front and rear surfaces includes a toric optical zone and a lens edge surrounding the contact lens (1). The contact lens further has a ballast axis (3) and includes at least one ballast mark (41, 42, 43) identifying the position of the ballast axis (3). ... Novartis Ag

02/01/18 / #20180030061

Novel pyrazolo pyrimidine derivatives and their use as malt1 inhbitors

The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with malt1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with malt1 proteolytic and/or autoproteolytic activity.. ... Novartis Ag

02/01/18 / #20180030004

Isoxazole hydroxamic acid compounds as lpxc inhibitors

This invention pertains generally to compounds of formula i as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by gram-negative bacteria.. ... Novartis Ag

02/01/18 / #20180028497

Panobinostat dosages for multiple myeloma

Treatment of multiple myeloma with a combination of panobinostat and bortezomib at specified doses adjusted for safety.. . ... Novartis Ag

02/01/18 / #20180028359

Pressure control in phacoemulsification system

A surgical system comprises a pressurized irrigation fluid source with a flexible bag located between two opposing plates. An irrigation line is fluidly coupled to the pressurized irrigation fluid source. ... Novartis Ag

02/01/18 / #20180028355

Integrated ophthalmic surgical system

An ophthalmic surgical system includes a chassis comprising a laser source. The system includes a gantry coupled to the chassis. ... Novartis Ag

02/01/18 / #20180028354

Method and apparatus for performing ophthalmic procedures removing undesirable features using laser energy

A method and system perform an ophthalmic procedure on an eye having an optical path from the lens to the retina. An image of at least part of the eye is received in a data processing unit. ... Novartis Ag

01/25/18 / #20180024077

Method for inspecting an ophthalmic lens using optical coherence tomography

A method for inspecting an ophthalmic lens, such as a contact lens, using optical coherence tomography. The method includes illuminating a sample volume including the lens with a sample light beam which is provided from a light source having a power of at least 2 mw at a wavelength of 1040 nm to 1080 nm and which does not exceed 5 w. ... Novartis Ag

01/25/18 / #20180022825

Reversal binding agents for anti-factor xi/xia antibodies and uses thereof

The present disclosure relates to reversal agents, which specifically bind to anti-factor xi and/or anti-factor xia antibodies, and reverse one or more anticoagulant effects of the anti-factor xi and/or anti-factor xia antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-factor xi and/or anti-factor xia antibodies, and to related methods for managing bleeding or bleeding risks.. . ... Novartis Ag

01/25/18 / #20180022811

Chemokine receptor binding polypeptides

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor cxcr2 and in particular to polypeptides capable of modulating signal transduction from cxcr2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of cxcr2.. ... Novartis Ag

01/25/18 / #20180022690

Process and intermediates for the preparation of nep inhibitors

The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (nep) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new chemical synthesis route.. ... Novartis Ag

01/25/18 / #20180021345

Autotaxin inhibitors

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.. . ... Novartis Ag

01/25/18 / #20180021101

Methods and systems for pulsed illumination

Methods and systems for performing an ophthalmic surgical procedure include pulsed illumination of target tissue. The systems may include an illumination instrument arranged to illuminate tissue at a surgical site during the ophthalmic surgical procedure. ... Novartis Ag

01/18/18 / #20180018953

Active noise cancellation in an ophthalmic surgical system

Active noise cancellation is employed to address unwanted acoustical noise generated by various equipment associated with an ophthalmic surgical system. Active noise cancellation may be used within a chassis of the ophthalmic surgical system, within an air compressor used with the ophthalmic surgical system, and within a reciprocating surgical probe used with the ophthalmic surgical system.. ... Novartis Ag

01/18/18 / #20180018780

Adaptive adjustment of overlay image parameters

Image parameters of an overlay image may be adjusted based on image parameters of an optical image displayed in a surgical microscope. The overlay image may then be displayed with the optical image to a user of the surgical microscope.. ... Novartis Ag

01/18/18 / #20180017776

Variable working distance microscope

A system and method for a variable working distance microscope is disclosed. The variable working distance microscope includes an eyepiece; a binocular system optically coupled to the eyepiece; a stereo zoom system optically coupled to the eyepiece and the binocular system; and a variable working distance lens system optically coupled to the eyepiece, the stereo zoom system, and the binocular system. ... Novartis Ag

01/18/18 / #20180017739

Optical fiber coupling reliability

Improved optical fiber coupling reliability is realized by improving structures and materials used at the fiber joint. When ceramic ferrules are used at the fiber joint, the penetration of a uv-cured optical adhesive between the ceramic ferrules and the fiber ends is avoided or prevented, while an anti-reflective coating, an uncured optical adhesive, or a refractive index matching gel may be applied between the ceramic ferrules. ... Novartis Ag

01/18/18 / #20180015092

Pharmaceutical combinations

The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (s)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2h-isoquinolin-3-one or (s)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1h-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (cdk4/6) inhibitor 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. ... Novartis Ag

01/18/18 / #20180014904

Optical and digital visualization in a surgical microscope

A surgical microscope may support intraoperative viewing of optical and digital images of a surgical site during surgery. The optical images may be viewed using an optical beam path from an objective lens of the surgical microscope. ... Novartis Ag

01/11/18 / #the present invention provides a compound of formula i:

Novartis Ag

. . ... Novartis Ag

01/11/18 / #20180011988

Application unlock using a connected physical device and transfer of data therebetween

According to one embodiment, a system includes a medical device configured to provide a function to a user, communicate via a wireless communication channel with one or more other devices, and send a signal to shift a medical device application from a locked state to an unlocked state. The system also includes a computing device having wireless communication channels and a processor and logic integrated with and/or executable by the processor. ... Novartis Ag

01/11/18 / #20180010132

Inhibition of prmt5 to treat mtap-deficiency-related diseases

The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is mtap-deficient and/or mta-accumulating and thus amenable to therapeutic treatment with a prmt5 inhibitor. Kits, methods of screening for candidate prmt5 inhibitors, and associated methods of treatment are also provided.. ... Novartis Ag

01/11/18 / #20180009889

Antibodies against notch 3

The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a notch 3 or mutant notch 3 receptor; and compositions and methods of use thereof.. . ... Novartis Ag

01/11/18 / #20180009801

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

The present invention relates to salts of (r)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.. . ... Novartis Ag

01/11/18 / #20180008706

Methods of treating psoriatic arthritis using il-17 antagonists

The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an il-17 antagonist, e.g., il-17 binding molecule (e.g., il-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or il-17 receptor binding molecule (e.g., il-17 antibody or antigen binding fragment thereof).. . ... Novartis Ag

01/11/18 / #20180008611

Method for treating otic infections after tympanostomy tube placement

The present invention relates to methods for treating a microbial infection comprising administering a composition comprising one or more antibiotic compounds to the site of the infection by instilling the composition into the tympanostomy tube. A delivery cannula can be used to instill the composition into the tympanostomy tube.. ... Novartis Ag

01/11/18 / #20180008463

Vitrectomy probe with rotary cutter and associated devices, systems, and methods

Systems, apparatuses, and methods of and for an ophthalmic surgical system are disclosed. An ophthalmic surgical system may include a vitrectomy probe having a housing sized and shaped for grasping by a user. ... Novartis Ag

01/04/18 / #the present invention relates to methods for modulating the wnt signaling pathway using compounds of formula (1),

Novartis Ag

. . ... Novartis Ag

01/04/18 / #20180002368

Novel 3' end caps, 5' end caps and combinations thereof for therapeutic rna

The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.. ... Novartis Ag

01/04/18 / #20180002292

Process for the production of condensed imidazolo derivatives

The present invention relates to a process for providing the compound of formula i, comprising the step of reacting a compound of formula vii with a base in the presence of an alkaline- or alkaline earth metal salt (mx), wherein lg is a leaving group. The presence of an alkaline- or alkaline earth metal salt was surprisingly found to render said reaction highly reliable in terms of the yield and purity of the compound of formula i obtained. ... Novartis Ag

01/04/18 / #20180000785

Methods for treating degenerative diseases/injuries

Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide tpo receptor agonist to such mammal.. . ... Novartis Ag

12/28/17 / #20170369473

Pyrrolidine derivatives as angiotensin ii type 2 antagonists

The invention relates to heterocyclic angiotensin ii type 2 (at2) receptor antagonists of formula (i), and pharmaceutically acceptable salts thereof, ((i) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof,combinations thereof, and their use as medic-aments, particularly for the treatment of neuropathic or inflammatory pain.. . ... Novartis Ag

12/28/17 / #20170368044

Pim kinase inhibitor combinations

The present invention relates to a pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a jak inhibitor compound, (b) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.. ... Novartis Ag

12/28/17 / #20170368038

Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases

The invention provides methods for modulating the activity of farnesoid x receptors (fxrs) using compounds of formula (i) or (ii). In particular, the invention provides for the use of compounds of formula (i) or (ii), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.. ... Novartis Ag

12/28/17 / #20170368001

Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

The present invention relates to stable compositions comprising a sphingosine 1 phosphate (s1p) receptor modulator, suitable for use as a dosage form. The s1p receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. ... Novartis Ag

12/28/17 / #20170367886

Graphical user interface system and method for representing and controlling surgical parameters

Graphical user interface system and method for displaying and controlling a surgical device, such as a device used in phacoemulsfication procedures. A graphical user interface is displayed on a display screen and includes one or more representations of operating parameters, such as aspiration rate, vacuum, and power that are used to control the surgical device. ... Novartis Ag

12/28/17 / #20170367885

Phacoemulsification handpiece with flexible impeller pump

A phacoemulsification system that includes a hand-graspable body and a phacoemulsification needle extending from a distal portion of the body is disclosed herein. The phacoemulsification system may also include an impeller pump carried by the hand-graspable body and configured to convey an aspiration fluid from a surgical site. ... Novartis Ag

12/28/17 / #20170367818

Iol delivery systems

An intraocular lens (iol) insertion apparatus includes a handpiece body having a distal tip and a proximal section. The iol insertion apparatus also includes a folding chamber located within the handpiece body, the folding chamber shaped to fold an iol advancing through the folding chamber. ... Novartis Ag

12/28/17 / #20170367817

Intraocular lens delivery device with telescoping plunger

An intraocular lens (iol) insertion apparatus may include a hand piece body having a distal tip, an iol folding chamber, and iol a dwell position, and a telescoping plunger having a first plunger portion and a second plunger portion. The first plunger portion and second plunger portion may be arranged to simultaneously advance through a first portion of a displacement of the telescoping plunger, and one of the first and second plunger portions may be arranged to advance through a second portion of the displacement of the telescoping plunger.. ... Novartis Ag

12/28/17 / #20170367816

Systems and methods for intraocular lens deployment

An intraocular lens (iol) insertion apparatus may include a handpiece body having a distal tip and a deployment chamber located at a distal end of the handpiece body. The deployment chamber is sized and shaped to hold a folded iol. ... Novartis Ag

12/21/17 / #20170362326

Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies

The present invention relates to antibodies targeting lrp6 and compositions and methods of use thereof.. . ... Novartis Ag

12/21/17 / #20170360603

Membrane delamination devices

Various membrane delamination devices for removing proliferative membranes from underling tissues are disclosed herein. In some implementations, the delamination device may include a first shearing part and a second shearing part. ... Novartis Ag

12/14/17 / #20170356608

Ophthalmic illumination system with controlled chromaticity

An ophthalmic illumination system includes a light source to emit a light beam and a filter comprising a clear region to transmit visible light in the visible spectrum and a first filtered region to transmit visible light in a first spectral range. The filter is arranged within the optical path of the beam. ... Novartis Ag

12/14/17 / #20170356006

Optimized expression cassette for expressing a polypeptide with high yield

The present invention is based on the finding that the combination of a specific 5′utr polynucleotide sequence (see seq id no 1) and the hcd33 secretory leader sequence in an expression cassette for expressing a polypeptide of interest results in a surprisingly better expression level of the polypeptide of interest compared to prior art expression cassettes. Based on this finding, the present invention inter alia provides novel expression cassettes, expression vectors and methods for producing a polypeptide of interest with high yield.. ... Novartis Ag

12/14/17 / #20170355762

Il-17 antagonistic antibodies

An il-17 binding molecule, in particular an antibody to human il-17, more preferably a human antibody to human il-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an il-17 mediated disease or disorder, e.g. Rheumatoid arthritis.. ... Novartis Ag

12/14/17 / #20170355684

Crystalline isoxazole hydroxamic acid compounds

This invention pertains to a crystalline compound of formula (a) as described herein and compositions containing this crystalline compound, as well as methods of using the compound or pharmaceutical compositions comprising it to treat bacterial infections. The compound and compositions are especially useful to treat gram negative bacterial infections, including multi-drug resistant strains.. ... Novartis Ag

12/14/17 / #20170355677

Synthesis of 2-carboxamide cycloamino urea derivatives

Provided herein are processes and intermediate compounds useful for the preparation of 2-carboxamide cycloamino urea derivatives, and useful intermediates therefore.. . ... Novartis Ag

12/07/17 / #20170348294

Use of alpha 7 nicotinic acetylcholine receptor agonists

The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.. . ... Novartis Ag

12/07/17 / #20170348091

Dual region accommodating intraocular lens devices, systems, and methods

Disclosed herein is an implantable accommodative iol device for insertion into an eye of a patient, comprising an active region and a passive region. The active region has a first thickness and first refractive index, and the active region comprises an electrically responsive optical lens having variable optical power. ... Novartis Ag

11/30/17 / #the present invention inter alia pertains to a method for generating or selecting a eukaryotic host cell expressing a desired level of a polypeptide of interest, comprising:

Novartis Ag

. . ... Novartis Ag

11/30/17 / #20170340733

Combination therapies

Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.. ... Novartis Ag








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Novartis Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Novartis Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###